Articoli con mandati relativi all'accesso pubblico - Zoran RankovicUlteriori informazioni
Non disponibile pubblicamente: 1
New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science
J Aubé, CW Lindsley, CE Müller, RW Sabnis, C Adam, TL Bray, ...
J. Med. Chem 66 (12), 7669-7669, 2023
Mandati: US National Institutes of Health
Disponibili pubblicamente: 33
Biased agonism: An emerging paradigm in GPCR drug discovery
Z Rankovic, TF Brust, LM Bohn
Bioorganic & medicinal chemistry letters 26 (2), 241-250, 2016
Mandati: US National Institutes of Health
Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs
J Min, A Mayasundari, F Keramatnia, B Jonchere, SW Yang, J Jarusiewicz, ...
Angewandte Chemie International Edition 60 (51), 26663-26670, 2021
Mandati: US National Institutes of Health
Identification of potent, selective, and orally bioavailable small-molecule GSPT1/2 degraders from a focused library of cereblon modulators
G Nishiguchi, F Keramatnia, J Min, Y Chang, B Jonchere, S Das, M Actis, ...
Journal of medicinal chemistry 64 (11), 7296-7311, 2021
Mandati: US National Institutes of Health, Alex's Lemonade Stand
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
Y Chang, J Min, JA Jarusiewicz, M Actis, S Yu-Chen Bradford, ...
Blood, The Journal of the American Society of Hematology 138 (23), 2313-2326, 2021
Mandati: US National Institutes of Health
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma
C He, K Xu, X Zhu, PS Dunphy, B Gudenas, W Lin, N Twarog, LD Hover, ...
Nature communications 12 (1), 4089, 2021
Mandati: US National Institutes of Health
Development of second-generation CDK2 inhibitors for the prevention of cisplatin-induced hearing loss
RA Hazlitt, T Teitz, JD Bonga, J Fang, S Diao, L Iconaru, L Yang, ...
Journal of medicinal chemistry 61 (17), 7700-7709, 2018
Mandati: US Department of Defense, US National Institutes of Health
Ca2+-mediated mitochondrial inner membrane permeabilization induces cell death independently of Bax and Bak
G Quarato, F Llambi, CS Guy, J Min, M Actis, H Sun, S Narina, ...
Cell Death & Differentiation 29 (7), 1318-1334, 2022
Mandati: US National Institutes of Health
AZD5438-PROTAC: a selective CDK2 degrader that protects against cisplatin-and noise-induced hearing loss
S Hati, M Zallocchi, R Hazlitt, Y Li, S Vijayakumar, J Min, Z Rankovic, ...
European journal of medicinal chemistry 226, 113849, 2021
Mandati: US Department of Defense, US National Institutes of Health
Phenyl dihydrouracil: an alternative cereblon binder for PROTAC design
JA Jarusiewicz, S Yoshimura, A Mayasundari, M Actis, A Aggarwal, ...
ACS Medicinal Chemistry Letters 14 (2), 141-145, 2023
Mandati: US National Institutes of Health
Targeting KDM4 for treating PAX3-FOXO1–driven alveolar rhabdomyosarcoma
S Singh, A Abu-Zaid, H Jin, J Fang, Q Wu, T Wang, H Feng, W Quarni, ...
Science translational medicine 14 (653), eabq2096, 2022
Mandati: US Department of Energy, US National Institutes of Health
Development of Potent and Selective Janus Kinase 2/3 Directing PG–PROTACs
LJ Alcock, Y Chang, JA Jarusiewicz, M Actis, S Nithianantham, ...
ACS medicinal chemistry letters 13 (3), 475-482, 2022
Mandati: US National Institutes of Health
Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases
SW Yang, X Huang, W Lin, J Min, DJ Miller, A Mayasundari, P Rodrigues, ...
Nature Communications 11 (1), 4931, 2020
Mandati: US Department of Energy, US National Institutes of Health
Recent advances with KDM4 inhibitors and potential applications
Q Wu, B Young, Y Wang, AM Davidoff, Z Rankovic, J Yang
Journal of medicinal chemistry 65 (14), 9564-9579, 2022
Mandati: US National Institutes of Health
Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia
CS Park, H Yoshihara, Q Gao, C Qu, I Iacobucci, PS Ghate, JP Connelly, ...
Cell reports 42 (7), 2023
Mandati: US National Institutes of Health, Alex's Lemonade Stand
Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia
J Hu, J Jarusiewicz, G Du, G Nishiguchi, S Yoshimura, JC Panetta, Z Li, ...
Science translational medicine 14 (659), eabo5228, 2022
Mandati: US National Institutes of Health
The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia
Y Chang, F Keramatnia, PS Ghate, G Nishiguchi, Q Gao, I Iacobucci, ...
Blood 142 (7), 629-642, 2023
Mandati: US National Institutes of Health, Alex's Lemonade Stand
Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
B Jonchere, J Williams, F Zindy, J Liu, S Robinson, DM Farmer, J Min, ...
Molecular cancer therapeutics 22 (1), 37-51, 2023
Mandati: US National Institutes of Health
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines
G Nishiguchi, LG Mascibroda, SM Young, EA Caine, S Abdelhamed, ...
Nature Communications 15 (1), 482, 2024
Mandati: Alex's Lemonade Stand
Evaluating and evolving a screening library in academia: the St Jude approach
G Nishiguchi, S Das, J Ochoada, H Long, RE Lee, Z Rankovic, AA Shelat
Drug discovery today 26 (4), 1060-1069, 2021
Mandati: US National Institutes of Health
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software